HK Stock Market Move | LEADS BIOLABS-B(09887) rises over 6% as the first systemic lupus erythematosus patient is dosed in Part B of the Phase I study of LBL-047

LEADS BIOLABS-B(09887) rose over 6%, up 6.28% as of press time at HK$36.24, with turnover of HK$29.0492 million. On the news front, LEADS BIOLABS-B announced that Part B of the Phase I clinical study (LBL-047CN001) of LBL-047 (known as DNTH212 outside Greater China), a novel bispecific fusion protein independently developed by the company targeting blood dendritic cell antigen 2 (BDCA2) and transmembrane activator and calcium-modulating cyclophilin ligand interactor (TACI), has successfully completed dosing of the first systemic lupus erythematosus (SLE) patient. The announcement stated that this is the first time LBL-047 has entered the autoimmune disease patient population. The molecule acts on two clinically validated pathogenic pathwaysinnate immunity and adaptive immunitysimultaneously, and LBL-047 features a complementary and differentiated dual-target design, marking its first direct validation in patients.